156 related articles for article (PubMed ID: 1931707)
1. Interferon alpha in the therapy of CML.
Talpaz M; Kantarjian H; Kurzrock R; Gutterman JU
Br J Haematol; 1991 Oct; 79 Suppl 1():38-41. PubMed ID: 1931707
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up results of alpha interferon therapy in chronic myelogenous leukemia at M. D. Anderson Cancer Center.
Kantarjian HM; Talpaz M
Leuk Lymphoma; 1993; 11 Suppl 1():169-74. PubMed ID: 8251891
[No Abstract] [Full Text] [Related]
3. CML: new biologic therapies, endpoints and questions.
Martin A; Cheson BD
Oncology (Williston Park); 1987 Sep; 1(7):12-3, 16. PubMed ID: 3152809
[No Abstract] [Full Text] [Related]
4. Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy.
Martinelli G; Testoni N; Amabile M; Bonifazi F; De Vivo A; Farabegoli P; Terragna C; Montefusco V; Ottaviani E; Saglio G; Russo D; Baccarani M; Rosti G; Tura S
Bone Marrow Transplant; 2000 Apr; 25(7):729-36. PubMed ID: 10745258
[TBL] [Abstract][Full Text] [Related]
5. Sequential treatment of Ph-positive chronic myeloid leukemia with interferon gamma and interferon alpha.
Russo D; Fanin R; Zuffa E; Damiani D; Gallizia C; Michieli M; Testoni N; Benfenati D; Visani G; Zaccaria A
Haematologica; 1990; 75(4):334-9. PubMed ID: 2125966
[TBL] [Abstract][Full Text] [Related]
6. A multicentric randomised study of alpha 2b interferon (IFN) and hydroxyurea (HU) with or without cytosine-arabinoside (Ara-c) in previously untreated patients with Ph+ chronic myelocytic leukemia (CML): preliminary cytogenetic results.
Guilhot F; Abgrall JF; Harousseau JL; Bauters F; Brice P; Dine G; Tilly H; Ifrah N; Cassasus P; Rochant H
Leuk Lymphoma; 1993; 11 Suppl 1():181-3. PubMed ID: 8251893
[TBL] [Abstract][Full Text] [Related]
7. A prospective randomized comparison of single-agent interferon (IFN)-alpha with the combination of IFN-alpha and low-dose IFN-gamma in chronic myelogenous leukaemia.
Kloke O; Wandl U; Opalka B; Moritz T; Nagel-Hiemke M; Franz T; Becher R; Hirche H; Seeber S; Niederle N
Eur J Haematol; 1992 Feb; 48(2):93-8. PubMed ID: 1547881
[TBL] [Abstract][Full Text] [Related]
8. Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older.
Cortes J; Kantarjian H; O'Brien S; Robertson LE; Pierce S; Talpaz M
Am J Med; 1996 Apr; 100(4):452-5. PubMed ID: 8610733
[TBL] [Abstract][Full Text] [Related]
9. Treatment of chronic myelogenous leukemia with interferons: hematologic, cellular, and genetic investigations.
Opalka B; Kloke O; Wandl U; Becher R; Niederle N
Haematol Blood Transfus; 1989; 32():134-8. PubMed ID: 2516494
[No Abstract] [Full Text] [Related]
10. Long-term treatment of chronic myelogenous leukemia with different interferons: results from three studies.
Niederle N; Kloke O; Wandl UB; Becher R; Moritz T; Opalka B
Leuk Lymphoma; 1993 Jan; 9(1-2):111-9. PubMed ID: 8477190
[TBL] [Abstract][Full Text] [Related]
11. [Interferon therapy for chronic myelogenous leukemia].
Shibata A; Hashimoto S
Gan To Kagaku Ryoho; 1993 Feb; 20(2):200-6. PubMed ID: 8434957
[TBL] [Abstract][Full Text] [Related]
12. Treatment of chronic myelogenous leukemia with different cytokines.
Wandl UB; Opalka B; Kloke O; Nagel-Hiemke M; Moritz T; Niederle N
Semin Oncol; 1992 Apr; 19(2 Suppl 4):88-94. PubMed ID: 1553580
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside.
Garcia-Manero G; Talpaz M; Giles FJ; Cortes J; Faderl S; O'Brien S; Thomas D; Verstovsek S; Beth Rios M; Shan J; Ferrajoli A; Wierda W; Kantarjian HM
Cancer; 2003 Jun; 97(12):3010-6. PubMed ID: 12784336
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with interferon alpha-2b plus low-dose interferon gamma in pretreated patients with Ph-positive chronic myelogenous leukaemia.
Wandl UB; Kloke O; Nagel-Hiemke M; Moritz T; Becher R; Opalka B; Holtkamp W; Bartels H; Seeber S; Niederle N
Br J Haematol; 1992 Aug; 81(4):516-9. PubMed ID: 1390238
[TBL] [Abstract][Full Text] [Related]
15. Treatment with natural human interferon alpha of a CML-patient with antibodies to recombinant interferon alpha-2b.
Freund M; von Wussow P; Knüver-Hopf J; Mohr H; Pohl U; Exeriede G; Link H; Wilke HJ; Poliwoda H
Blut; 1988 Nov; 57(5):311-5. PubMed ID: 3196882
[TBL] [Abstract][Full Text] [Related]
16. A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia.
Talpaz M; Kurzrock R; Kantarjian H; Rothberg J; Saks S; Evans L; Gutterman JU
Cancer; 1991 Nov; 68(10):2125-30. PubMed ID: 1913450
[TBL] [Abstract][Full Text] [Related]
17. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
[TBL] [Abstract][Full Text] [Related]
18. Evolving approaches with interferon alfa in chronic myelogenous leukemia.
Morra E; Alimena G; Lazzarino M; Liberati AM; Montefusco E; Bernasconi P; Mancini M; Donti E; Merante S; Caricchi P
Semin Hematol; 1993 Jul; 30(3 Suppl 3):26-7. PubMed ID: 8235701
[No Abstract] [Full Text] [Related]
19. Hypertriglyceridemia may be severe in CML patients treated with interferon-alpha.
Peñarrubia MJ; Steegmann JL; Lavilla E; Casado F; Requena MJ; Picó M; Arranz R; Fernández-Rañada JM
Am J Hematol; 1995 Jul; 49(3):240-1. PubMed ID: 7604817
[TBL] [Abstract][Full Text] [Related]
20. Combined therapy interferon and chemotherapy in chronic myelogenous leukemia.
Guilhot F; Dreyfus B; Desmarest MC; Giraud C; Huret JL; Brizard A; Tanzer J
Nouv Rev Fr Hematol (1978); 1989; 31(2):171-3. PubMed ID: 2771633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]